286,207 Shares in Metsera Inc. $MTSR Bought by American Century Companies Inc.

Key Points

• American Century Companies Inc. acquired a new stake in Metsera Inc. with approximately $7.79 million for 286,207 shares, representing about 0.27% ownership of the company.
• Major institutional investments in Metsera include Alphabet Inc. with a stake valued at around $135 million and Vanguard Group Inc. with approximately $39.93 million.
• Research firms are optimistic about Metsera, with Wells Fargo giving it an "overweight" rating and a price objective of $65.00, while Guggenheim raised its price target to $62.00.

American Century Companies Inc. acquired a new position in Metsera Inc. (NASDAQ:MTSR - Free Report) during the first quarter, according to its most recent filing with the SEC. The firm acquired 286,207 shares of the company's stock, valued at approximately $7,791,000. American Century Companies Inc. owned about 0.27% of Metsera as of its most recent filing with the SEC.

Other large investors have also recently made changes to their positions in the company. New York State Common Retirement Fund bought a new stake in shares of Metsera in the 1st quarter worth approximately $131,000. Invesco Ltd. bought a new stake in shares of Metsera in the 1st quarter worth approximately $271,000. Deutsche Bank AG bought a new stake in shares of Metsera in the 1st quarter worth approximately $374,000. Nuveen LLC purchased a new position in shares of Metsera in the 1st quarter valued at approximately $553,000. Finally, Bank of New York Mellon Corp purchased a new position in shares of Metsera in the 1st quarter valued at approximately $884,000.

Metsera Stock Up 2.6%

Shares of MTSR stock traded up $0.92 during mid-day trading on Tuesday, hitting $36.21. The company's stock had a trading volume of 1,297,315 shares, compared to its average volume of 1,278,951. Metsera Inc. has a 52-week low of $12.30 and a 52-week high of $47.40. The business has a 50-day moving average price of $34.25 and a 200 day moving average price of $28.56.

Metsera (NASDAQ:MTSR - Get Free Report) last posted its quarterly earnings results on Monday, July 28th. The company reported ($0.66) earnings per share for the quarter.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on MTSR shares. Wall Street Zen upgraded Metsera from a "sell" rating to a "hold" rating in a research note on Saturday. Guggenheim raised their target price on Metsera from $56.00 to $62.00 and gave the company a "buy" rating in a research note on Tuesday, June 10th. Bank of America raised their target price on Metsera from $45.00 to $50.00 and gave the company a "buy" rating in a research note on Thursday, August 28th. Finally, Wells Fargo & Company started coverage on Metsera in a research note on Friday, June 20th. They issued an "overweight" rating and a $65.00 target price for the company. Five investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $59.00.

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.